Literature DB >> 494251

Experimental and clinical studies on toxicity of xenogeneic tumor-specific immune ribonucleic acid.

M Fukushima, S Fukuda, S Machida, Y Ishikawa.   

Abstract

To learn the toxicity of xenogeneic tumor-specific immune ribonucleic acid (I-RNA), experimental and clinical studies were carried out. Experimentally, doses of 30 mg/kg, 15 mg/kg, 7.5 mg/kg or 3.75 mg/kg of xenogeneic I-RNA extracted from lymphoid tissues of rabbits sensitized with 105,000 Xg sediments of human gastric carcinoma tissue were injected intraperitoneally into Wistar rats once a day for 30 days. During the period of the study, changes of physiological and biochemical values were examined. In addition, pathological study was made for each organ after the I-RNA administration. There was no death during the study. In the groups of high dose administration, there were poor increase in the body weight, elevation of GOT, GPT and LDH, findings of vacuolar degeneration of hepatic cells, and increase of mesangial matrix and polynuclear glomerulus. Throughout the experiment, the groups given 7.5 mg/kg and 3.75 mg/kg of I-RNA showed no significant difference from control groups. Clinically, 31 cases treated with passive immunotherapy with allogeneic lymphocytes, preincubated with xenogeneic I-RNA, were examined retrospectively for the difference in hematological and biochemical data before and after the therapy. One case showed a transient mild febrile reaction after the therapy. There was no significant difference in hematological and biochemical data. Pathological findings in 3 autopsies after the treatment were reported.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 494251     DOI: 10.1620/tjem.128.285

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  1 in total

1.  Specific immunotherapy for non-curatively resected gastric cancer.

Authors:  Y Ishikawa; H Kakuta; M Fukushima; S Machida; S Fukuda
Journal:  Jpn J Surg       Date:  1979-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.